Matta MK, Florian J, Zusterzeel R, et al. - A randomized clinical trial was designed to evaluate the systemic absorption and pharmacokinetics of the 6 active ingredients (avobenzone, oxybenzone, octocrylene, homosalate, octisalate, and octinoxate) in 4 sunscreen products under single- and maximal-use conditions. They included 48 individuals (mean [SD] age, 38.7 [13.2] years; 24 women [50%]; 23 white [48%], 23 African American [48%], 1 Asian [2%], and 1 of unknown race/ethnicity [2%]), 44 (92%) performed the trial. Individuals were assigned randomly to 1 of 4 sunscreen products, formulated as a lotion, aerosol spray, nonaerosol spray, and pump spray. They used sunscreen products at 2 mg/cm2 to 75% of body surface area at 0 hours on day 1 and 4 times on day 2 through day 4 at 2-hour intervals, and 34 blood samples were collected over 21 days from each individual. This study performed in a clinical pharmacology unit and testing sunscreen application among healthy individuals, all 6 of the measured active ingredients administered in 4 different sunscreen formulations were systemically absorbed and had plasma concentrations that surpassed the FDA threshold for potentially waiving some of the additional safety studies for sunscreens. The results do not show that individuals should refrain from the application of sunscreen.